News Ocrevus Approved in UK as First NHS Treatment for PPMS Ocrevus Approved in UK as First NHS Treatment for PPMS by Joana Carvalho, PhD | May 13, 2019 Share this article: Share article via email Copy article link After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now approved the use of Ocrevus (ocrelizumab) for people in the U.K. with early, inflammatory primary progressive multiple sclerosis (PPMS). This means that PPMS patients living in the U.K. will now have access to Ocrevus treatment through the country’s National Health Service (NHS). To be eligible for treatment, patients must comply with three criteria: having experienced PPMS symptoms for 15 years or less; being able to walk at least 20 meters (about 65 feet) with or without assistance (which means having an EDSS score of up to 6.5); and having signs of disease activity on magnetic resonance imaging (MRI) scans. Initially, the decision will only apply to England. In the meantime, Genentech, a member of the Roche group — Ocrevus’ manufacturer — will work closely with the NHS in Wales and Northern Ireland, and the Scottish Medicines Consortium in Scotland, to ensure Ocrevus becomes available in all of the U.K. Ocrevus is the first approved NHS treatment for PPMS in the U.K., a landmark decision made possible only with the collective effort, and dedication, of MS support organizations, including the MS Trust, patients and physicians, a trust official said. After the initial rejection, the final decision was postponed to allow further discussions between NICE, the NHS and Roche. Before preparing its submission to NICE, the MS Trust conducted a survey of nearly 500 respondents, including MS patients, family members and MS specialists, gathering opinions from those affected by the disease as to whether Ocrevus should be approved as an NHS treatment. “This is very welcome news. We commend the willingness of all three parties to find a solution which enables people with early, inflammatory primary progressive MS to access a treatment which will allow them to continue working and remain independent for longer,” David Martin, CEO of MS Trust, said in a press release. “But we know this is just the start. More treatments for progressive MS are still desperately needed, and we will continue to fight to ensure everyone with MS can access the treatments they need,” Martin added. Yvonne Pettigrew, a patient diagnosed with PPMS, said about this approval: “I can’t tell you how exciting it is to have the first drug to treat PPMS, Ocrevus, approved for use within the NHS. I know there are of course strict constraints governing the people Ocrevus can be prescribed for which come from the research evidence of who can benefit, but I’m desperately hoping I am one of them. Control of my deterioration will give me optimism about a future I hadn’t dared dream about.” The NHS in England now will have three months to prepare before it starts funding the treatment for all eligible PPMS patients receiving Ocrevus prescriptions from their doctors. Print This Page About the Author Joana Carvalho, PhD Joana holds a bachelor’s in biology, a Master of Science in evolutionary and developmental biology, and a PhD in biomedical sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. Tags approval, Genentech, NICE, ocrelizumab, Ocrevus, PPMS, Roche
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression